CONMED Corp — Director's Dealing 2010

Jun 3, 2010

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CONMED CORP (CNMD)
CIK: 0000816956
Period of Report: 2010-06-01

Reporting Person: Jones Gregory Renard (Vice President-Corporate QA/RA)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-06-01	Common Stock	M	800	—	Acquired	1263	Direct
2010-06-01	Common Stock	F	290	—	Disposed	973	Direct
2010-06-01	Common Stock	M	750	—	Acquired	1723	Direct
2010-06-01	Common Stock	F	272	—	Disposed	1451	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-06-01	Rsus (restricted Stock Units)	$0	M	800	Disposed	2019-06-01	Common Stock (800)	Direct
2010-06-01	Rsus (restricted Stock Units)	$0	M	750	Disposed	2019-06-01	Common Stock (750)	Direct
2010-06-01	Rsus (restricted Stock Units)	$0	A	4000	Acquired	2020-06-01	Common Stock (4000)	Direct
2010-06-01	Rsus (restricted Stock Units)	$0	A	4000	Acquired	2020-06-01	Common Stock (4000)	Direct
2010-06-01	Sars (Stock Appreciation Rights)	$19.26	A	10000	Acquired	2020-06-01	Common Stock (10000)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the RSUs generally vesting over a five year period with the first 20% of the RSU's vesting one year after the grant date.

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2006 Stock Incentive Plan, with the RSUs vesting in equal amounts over a ten year period

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan, with the RSUs vesting over a seven year period with 14% of the RSU's vesting in the first through the fifth year after the grant date and 15% vesting in the sixth and seventh year.

F4: The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.